Send the following on WhatsApp
Continue to Chathttps://www.bfmtv.com/economie/patrimoine/placements-epargne/opsona-therapeutics-ltd-demarre-une-etude-de-phase-ii-avec-l-opn-305-un-anticorps-monoclonal-d-un-nouveau-genre-qui-bloque-le-recepteur-toll-like-de-type-2-chez-des-patients-ayant-subi-une-transplantation-renale-presentant-un-risque-eleve_AN-201305080191.html